Advances in Macrophage-Based Immunotherapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: 30 April 2024 | Viewed by 1570
Special Issue Editor
2. Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), 46010 Valencia, Spain
Interests: macrophages; fibrosis; TGF; WNT; myofibroblasts; MMT; NOTCH; complications; succinate; autophagy; senescence; chronic inflammation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Adoptive cellular therapies are making major strides in the treatment of many diseases, especially in cancer and fibrosis. Amongst cell types used in immunotherapies, macrophages are prominent candidates. Macrophages have critical functions in both innate and adaptive immune responses. They are present in almost every tissue, recognize exogenous/endogenous danger signals through pattern-recognition receptors, produce cytokines/chemokines that orchestrate immune responses, function as professional antigen-presenting cells, and are important elements in wound repair and fibrosis by regulating extracellular matrix turnover. The diversity of functions they perform is due to the fact that their phenotype is highly plastic and exists across a spectrum of pro- and anti-inflammatory states. Plasticity allows participating in numerous effector functions that could support chronic autoimmune diseases, tumor, or fibrosis clearance. The Special Issue “Advanced in Macrophage-Based Immunotherapy” aims to collect information on the use of cell therapy in different pathologies, with a special interest in therapy that uses reprogrammed macrophages capable of limiting the pathology by modifying the microenvironment, favoring the cleaning of cancer and fibrotic cells or promoting regeneration, among other processes.
Prof. Dr. Dolores Ortiz-Masiá
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- macrophages
- fibrosis
- cancer
- chronic inflammation
- autophagy
- apoptosis
- senescence
- immunotherapy
